Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360506 | 0.74 | HRH3 (0.44) | HRH3KDM1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL25754643 | 0.73 | SIGMAR1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL25754642 | 0.71 | HRH3 (0.35) | HRH3KDM1AL3MBTL1L3MBTL3ALDH1A1 | |
| SCHEMBL25754416 | 0.71 | HRH3 (0.38) | HRH3 | |
| SCHEMBL24783666 | 0.70 | HRH3 (0.47) | HRH3KDM1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL18951862 | 0.70 | SMN1; SMN2 (0.57) | HRH3KDM1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL1309460 | 0.70 | ALOX15 (0.48) | HRH3KDM1AL3MBTL1L3MBTL3ALDH1A1 | |
| SCHEMBL25754413 | 0.70 | MAPT (0.36) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL25754436 | 0.69 | KDM4E (0.36) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL22477392 | 0.68 | HRH3 (0.39) | HRH3KDM1AL3MBTL1L3MBTL3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HRH3 1596/4885KDM1A 984/4885L3MBTL1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.